Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Cisplatin 6Standard of Care 5Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5toripalimab 4Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Radiation 3Prednisone 3Population Groups 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × trilaciclib × 1 year × Clear all
NCT06370416 2026-01-28

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Henan Cancer Hospital

Phase 2 Enrolling by invitation
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡